Colchester, VT – According to filings with the U.S. Securities and Exchange Commission, Vernal Biosciences is raising $20,998,407.00 in new funding. Sources indicate as part of senior management President, Christian Cobaugh played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vernal Biosciences
We are passionate about channeling Vernals technology and the hard work of our team to democratize mRNA R&D by making mRNA readily available to more researchers and companies. We believe that science matters more than ever and that mRNA will open many more doors for science to change the lives of humans everywhere. To help fulfill this vision, Vernal is committed to increasing access to the supply of quality mRNA. Before building Vernal Biosciences to open up access to this precious material, mRNA, we grew accustomed to the challenges of outsourcing mRNA manufacturing: unreliable supply, variable quality, regulatory confusion, and difficulty scaling the technology and business considerations from research to clinical needs. We will help you eliminate those challenges by leveraging the successes, and even occasional failures we had during our years-long odyssey of outsourcing mRNA. It turns out that outsourcing mRNA can be done properly through a deep alignment with your research and development needs.

To learn more about Vernal Biosciences, visit http://www.vernal.bio/

Contact:
Christian Cobaugh, President
512-791-9680
cobaughc@vernal.bio
https://www.linkedin.com/in/christian-cobaugh/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved